Canaccord Raises Guardant Health Price Target as Revenue Assumptions Improve
Canaccord Genuity increased its price target for Guardant Health to $135 from $125 and kept a Buy rating, citing stronger revenue assumptions in the outer years of its 10-year discounted cash flow model. Guardant reported fourth-quarter 2025 results in line with its January preannouncement, recorded $35.1 million in Shield revenue for Q4 and provid…